Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis

Main Article Content

Andrew Blauvelt
Jean-Philippe Lacour
Darryl Toth
Vivian Laquer
Stefan Beissert
Andreas Wollenberg
Pedro Herranz
Andrew Pink
Ketty Peris
Stine Fangel
Hidehisa Saeki

Keywords

tralokinumab, atopic dermatitis, ECZTEND

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109-22.

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274-9.e273.

3. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984-91.

5. Bieber T. Allergy. 2020;75:54-62.

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480-9.

7. Popovic B, et al. J Mol Biol. 2017;429:208-19.

8. Wollenberg A, et al. Br J Dermatol. 2021;184:437-49.

9. Silverberg JI, et al. Br J Dermatol. 2021;184:450-63.

10. Leshem YA, et al. Br J Dermatol. 2015;172:1353-7.

11. Hongbo Y, et al. J Invest Dermatol. 2005;125:659-64.

Most read articles by the same author(s)

1 2 3 4 5 > >>